Dr. Bruce Alan Kehr, Founder and President of Potomac Psychiatry, is a national thought leader in the field of psychiatry. He received his BA from the University of Pennsylvania, followed by an MD from the Georgetown University School of Medicine. He is Board Certified by the American Board of Psychiatry and Neurology.

He is also the Founder of PainScript, a digital health company that improves clinical outcomes for patients struggling with substance abuse disorders and chronic pain. He has pioneered a national consulting program in Root Cause Psychiatry, where he and his team of experts address the various root causes of emotional distress in treatment resistant patients, including genetic, gut microbiome, immunologic, cellular health, and other contributions to chronic emotional illness.

Through the use of innovative laboratory tests, the team builds a unique database of laboratory findings and recommended treatment interventions for each treatment resistant patient and presents these findings to the patient and their treating physician. He also provides empathetic psychotherapy for individuals, couples, and families, with a focus on professionals and senior executives.

Dr. Kehr's expertise is reflected in his extensive writings and patented inventions, targeting conditions such as anxiety, depression, PTSD, substance use disorder, and bipolar disorder. His accomplishments include being recognized as a "Top Doctor" by various publications and receiving national awards for his contributions to psychiatric care. He is an accomplished author whose works have been read by over 1,000,000 people in 206 countries.

Craig Shimasaki is President and CEO of Moleculera Labs, a neuroimmunology precision medicine company focused on identifying underlying roots of neurologic, psychiatric, and behavioral disorders triggered by an autoimmune response. He is a medical research scientist with over 35 years of translational development experience in biochemical interactions, molecular biology, viral pathogenesis and infection-triggered neuropsychiatric disorders.

Dr. Shimasaki has worked at all stages of research and development from bench to bedside. His research included epitope mapping of HIV proteins, genetic based risk predictors of breast cancer, influenza and RSV diagnostics and therapeutics and pathogenesis of infection triggered neuropsychiatric disorders. As a businessperson, he co-founded multiple companies and led multiple products through the FDA approval process and is a co-inventor on multiple patents.

Dr. Shimasaki started his career at Genentech. He received his BS in Biochemistry from University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor at the University of Oklahoma where he teaches biotechnology entrepreneurship. His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives.